Table 1.

Previously functionally validated SNPs affecting miRNA binding evaluated by TargetScan and miRanda.

SNP	Locus	Gene	Transcripta	miRNAb	Allelesc	Ref. allele		Alt. allele		Associated disease
						Context ++d	MFEe	Context ++d	MFEe
rs4245739[f21	1q32	MDM4	ENST00000367182.3	hsa-miR-191-5p	A/C	—	—	−0.309	—	Ovarian cancer
rs793013	1q42.3	TOMM20	ENST00000366607.4	hsa-miR-4273-5p	A/G	−0.151	—	—	—	Colorectal cancer
rs3559256722	3q28	TP63	ENST00000264731.3	hsa-miR-140-5p	C/T	−0.234	—	—	—	Bladder cancer
rs107173816	4q32.3	PALLD	ENST00000261509.6	hsa-miR-96-5p	G/C	—	—	−0.12	—	Breast cancer
				hsa-miR-182-5p		—	—	−0.298	—
			ENST00000335742.7	hsa-miR-96-5p		—	—	−0.126	—
				hsa-miR-182-5p		—	—	−0.317	—
rs1272020823	8p22	FGF20	ENST00000180166.5	hsa-miR-433-3p	G/A	−0.201	—	—	—	Parkinson’s disease
rs422524	11q23.3	APOC3	ENST00000227667.3	hsa-miR-4271	G/T	—	−16.69	−0.172	−21.07	Coronary heart disease
rs11540855f20	19p13.11	ABDH8	ENST00000247706.3	hsa-miR-4707-3p	A/G	—	−23.93	−0.225	−25.95	—

^aTranscript ID of the 3′-UTR sequence used in TargetScan’s miRNA-binding predictions

^bmiRNA ID from miRbase v21

^cReference allele/alternative allele(s)

^dObtained from TargetScan v7.1

^eMinimum free energy (MFE, from miRanda v3.3a) for the corresponding prediction obtained in TargetScan

^fSNP associated in GWAS with breast cancer risk, all others are proxies GWAS-significant variants in the corresponding loci